Skip to main content
S&P 5007,688.62+1.58%DOW53,356.12+3.03%NASDAQ25,736.51+1.44%BTC$80,683.00+3.69%ETH$2,436.19+6.33%GOLD$4,072.20-0.02%OIL$88.04-0.09%
Smart Investors Daily
SID Premium
IM

NASDAQ · IMCR

Immunocore Holdings plc

Healthcare · Biotechnology

$30.03

Down-$0.80 (-2.66%)

Updated Nov 4, 2026, 11:03 PM

SID Score

4.3/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.81B
P/E ratio
-63.88
Dividend yield
0.00%
52-week range
$27.50 – $37.95
Volume
253.27K
Avg. volume
310.24K

Price performance · IMCR

IMCR price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 3, 2026

IMCR closed at $30.03 after 21 trading sessions, up 1.62% for the selected period.

Last close
$30.03
Period change
+1.62%
Period low
$27.82
Period high
$32.61
Daily close
View OHLC price history
IMCR OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 3, 2026$29.83$30.95$29.83$30.03253.27K
Nov 2, 2026$30.56$30.825$29.64$29.79226.06K
Oct 30, 2026$31.00$31.4399$30.13$30.49290.23K
Oct 29, 2026$32.60$32.61$31.24$31.271.29M
Oct 28, 2026$31.61$32.72$30.01$32.61197.6K
Oct 27, 2026$31.22$32.00$31.04$31.96314.12K
Oct 26, 2026$31.32$31.74$30.95$31.28197.93K
Oct 23, 2026$31.78$31.80$30.94$30.98177.89K
Oct 22, 2026$32.04$32.785$31.2965$32.12283.25K
Oct 21, 2026$32.60$33.565$31.96$32.091.16M
Oct 20, 2026$29.70$32.75$29.70$32.60942.09K
Oct 19, 2026$29.36$29.98$29.05$29.84350.98K
Oct 16, 2026$29.53$30.17$28.62$29.40924.94K
Oct 15, 2026$28.73$29.90$28.73$29.48378.2K
Oct 14, 2026$27.60$28.45$27.50$28.34414.3K
Oct 13, 2026$29.00$29.25$27.645$27.82906.65K
Oct 12, 2026$29.48$29.725$29.02$29.04219.73K
Oct 9, 2026$29.06$29.73$29.03$29.39452.84K
Oct 8, 2026$29.19$29.62$28.66$29.09424.56K
Oct 7, 2026$29.55$29.82$29.15$29.41343.75K
Oct 6, 2026$29.93$30.345$29.40$29.55662.6K

Latest IMCR news

The latest Smart Investors Daily articles mentioning IMCR.

Stock researchCompany · Overview

IMCR research

Overview

Company profile and research snapshot.

Company profile

Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$48.00
Implied upside
—
Analysts
—
IMCR recent ratings
DateFirmRatingTarget
Oct 26, 2026HC Wainwright & Co.Buy—
Aug 21, 2026JP MorganOverweight—
Aug 3, 2026MizuhoNeutral—
Apr 20, 2026HC Wainwright & Co.Buy—
Apr 14, 2026HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 29, 2026

Immunocore will present Phase 1 data for brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma, during a late-breaking oral session at the 2026 SITC meeting

Immunocore will present Phase 1 data for brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma, during a late-breaking oral session at the 2026 SITC meeting Clinical data for first combination of two T cell engagers in a solid tumor will be presented in a poster on Friday, November 6, and an oral presentation on November 7 (OXFORDSHIRE, England & RADNOR, PA & GAITHERSBURG, MD, US, October 29, 2026) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a com

Yahoo · Oct 29, 2026

Should First Type 1 Diabetes Dosing Require Action From Immunocore Stock Investors?

Immunocore Holdings reported that the first type 1 diabetes patient has been dosed in its Phase 1 trial of IMC-S118AI, a bispecific therapy candidate designed to protect beta cells by binding preproinsulin on HLA-A*02:01-positive cells while activating a PD-1 agonist arm to dampen autoreactive T cells. This move into autoimmune disease, supported by Science Advances data in human pancreas tissue that show tissue-selective binding and T cell suppression, indicates an effort by Immunocore...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By